- Home
- RDWR vs CDTX Comparison
RDWR vs CDTX Comparison
Compare RDWR & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDWR
- CDTX
- Stock Information
- Founded
- RDWR 1996
- CDTX 2012
- Country
- RDWR Israel
- CDTX United States
- Employees
- RDWR N/A
- CDTX N/A
- Industry
- RDWR EDP Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDWR Technology
- CDTX Health Care
- Exchange
- RDWR Nasdaq
- CDTX Nasdaq
- Market Cap
- RDWR 1.0B
- CDTX 980.1M
- IPO Year
- RDWR 1999
- CDTX 2015
- Fundamental
- Price
- RDWR $28.56
- CDTX $48.89
- Analyst Decision
- RDWR Hold
- CDTX Strong Buy
- Analyst Count
- RDWR 4
- CDTX 11
- Target Price
- RDWR $27.00
- CDTX $52.11
- AVG Volume (30 Days)
- RDWR 497.0K
- CDTX 1.4M
- Earning Date
- RDWR 07-30-2025
- CDTX 08-12-2025
- Dividend Yield
- RDWR N/A
- CDTX N/A
- EPS Growth
- RDWR N/A
- CDTX N/A
- EPS
- RDWR 0.27
- CDTX N/A
- Revenue
- RDWR $281,874,000.00
- CDTX $302,000.00
- Revenue This Year
- RDWR $10.38
- CDTX N/A
- Revenue Next Year
- RDWR $7.14
- CDTX N/A
- P/E Ratio
- RDWR $109.76
- CDTX N/A
- Revenue Growth
- RDWR 9.54
- CDTX N/A
- 52 Week Low
- RDWR $17.36
- CDTX $10.14
- 52 Week High
- RDWR $31.57
- CDTX $56.83
- Technical
- Relative Strength Index (RSI)
- RDWR 56.21
- CDTX 73.52
- Support Level
- RDWR $29.00
- CDTX $45.59
- Resistance Level
- RDWR $31.57
- CDTX $52.33
- Average True Range (ATR)
- RDWR 0.80
- CDTX 5.13
- MACD
- RDWR -0.15
- CDTX 0.22
- Stochastic Oscillator
- RDWR 33.11
- CDTX 61.27
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.